External broker reports(aggregated public sources), Axis Direct

Axis Direct

Axis Direct is the flagship brand under Axis Securities Limited, a subsidiary of Axis Bank in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only.  Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

External broker reports(aggregated public sources)

Axis Direct is the flagship brand under Axis Securities Limited, a subsidiary of Axis Bank in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Equity Bottom-Up

<ul><li>Growth Driven by Base Business: Aurobindo reported Q3FY26 revenue of Rs 8,646 Cr marking 8.4% YoY and 4.3% QoQ growth.</li><li>Performance was supported by steady traction in the core base business, with the US contributing ~$420 Mn.</li><li>US Injectables segment also reported healthy growth of 17% YoY, while Europe formulations emerged as the key growth engine, delivering strong 27.4% YoY growth to Rs 2,703 Cr, reflecting improved product mix and capacity utilization. </li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

Growth Driven by Base Business: Aurobindo reported Q3FY26 revenue of Rs 8,646 Cr marking 8.4% YoY and 4.3% QoQ growth.Performance was supported by steady traction in the core base business, with the US contributing ~$420 Mn.US Injectables segment also reported healthy growth of 17% YoY, while Europe formulations emerged as the key growth engine, delivering strong 27.4% YoY growth to Rs 2,703 Cr, reflecting improved product mix and capacity utilization. Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Aurobindo Pharma

Aurobindo Pharma Ltd - Operational Beat